-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

1728 Copanlisib in Combination with Rituximab and Bendamustine for Transplant-Ineligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients: Results from the Phase II Multicenter Fil_Copa-Rb Trial from Fondazione Italiana Linfomi (FIL)

Program: Oral and Poster Abstracts
Session: 626. Aggressive Lymphomas: Prospective Therapeutic Trials: Poster I
Hematology Disease Topics & Pathways:
Biological therapies, Translational Research, Lymphomas, Non-Biological therapies, B Cell lymphoma, Chemotherapy, Diseases, aggressive lymphoma, Therapies, Immunotherapy, Lymphoid Malignancies
Saturday, December 9, 2023, 5:30 PM-7:30 PM

Pio Manlio Mirko Frascione, MD1*, Mattia Novo, MD2*, Alessia Castellino, MD3*, Luigi Marcheselli4*, Samantha Deianira Dattoli4*, Alessandra Tucci, MD5, Guido Gini, MD6,7, Giuseppe Tarantini, MD8*, Donato Mannina, MD9*, Annalisa Arcari, MD10*, Roberta Martiniani11*, Elisabetta Scarpa12*, Dario Marino, MD, PhD13*, Michele Spina, MD14*, Ausilia Giuseppa Gorgone15*, Nicola Di Renzo, MD16*, Salvatrice Mancuso17*, Luigi Petrucci, MD18*, Agostino Tafuri, MD19 and Umberto Vitolo, MD20

1Onco-Ematologia, Candiolo Cancer Institute- Fondazione del Piemonte per l'Oncologia-IRCCS, Candiolo, AL, Italy
2Hematology Division, A.O.U Città della Salute e della Scienza di Torino, Torino, Italy
3Hematology Unit, Santa Croce e Carle Hospital, Cuneo, Piemonte, ITA
4Fondazione Italiana Linfomi, Clinical Trial Office, Modena, Italy
5Hematology, ASST Spedali Civili, Brescia, Italy
6Hematology Unit, AOU delle Marche-Università Politecnica delle Marche, Ancona, Italy
7Clinica Di Ematologia Università Politecnica Delle Marche- Ospedali Riuni, Ancona, ITA
8Haematology, Ospedale "Mons. Dimiccoli", Barletta, Italy
9Division of Hematology, Azienda Ospedaliera Papardo, Messina, Messina, Italy
10Division of Hematology, Guglielmo da Saliceto Hospital, Piacenza, Italy
11University of Perugia, Terni, ITA
12Hematology, Ca Foncello Hospital, Treviso, ITA
13Oncologia 1, IRCCS Istituto Oncologico Veneto, Padova, Italy
14Division of Medical Oncology, IRCCS Centro Di Riferimento Oncologico, Aviano, Italy
15Hematology Department, G. Garibaldi Hospital, Catania, Italy
16Haematology, Ospedale V. Fazzi, Lecce, Italy, Lecce, Italy
17Policlinico Paolo Giaccone, Unit of Haematology, Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (ProMISE), University of Palermo, Palermo, Italy
18Department of Translational and Precision Medicine, 'Sapienza' University of Rome, Roma, ITA
19Azienda Ospedaliera Sant'Andrea, Rome, Italy
20Onco-Ematologia, Candiolo Cancer Institute- Fondazione del Piemonte per l'Oncologia-IRCCS, Candiolo, Italy

Background: 60% of Diffuse large B-cell lymphoma (DLBCL) are cured with R-CHOP. Treatment options for relapsed/refractory (R/R) patients (pts) not eligible to high-dose chemotherapy and autologous stem cell transpntation (ASCT) or CAR-T are limited with short-lasting efficacy. The PI3-K inhibitor copanlisib showed activity in B-cell lymphomas including DLBCL. We reported the results of the phase II single arm multicenter FIL Copa-RB trial which investigated the combination copanlisib plus rituximab and bendamustine (copa-RB) in transplant-ineligible R/R DLBCL.

Methods: Patients with R/R DLBCL previously treated with 1-3 prior lines, not eligible to ASCT and CAR-T were enrolled to receive 6 cycles of copa-RB q28 days (induction treatment schedule: copanlisib 60 mg i.v. days 1,8,15. Rituximab 375 mg/m2 i.v. day 1, Bendamustine 90 mg/m2 i.v. days 1,2). Patients with at least stable disease continued with a maintenance phase up to 12 q28 day cycles of Copanlisib (60 mg i.v. days 1,15). The primary end point was 12-month progression free survival (PFS) with an expected improvement from 20% to 35% and a calculated sample size of 81 pts.

Results: From 11/2019 to 7/2022, 37 pts were enrolled. Median age was 76 years (68-87), 23 (62%) were at IPI ≥3, 25 (68%) had stage IV, 23 (62%) and 14 (38%) received 1 and 2 prior lines and 35% were refractory to the last treatment. The best overall response rate (ORR) was 51%, with 22% CR. With a median follow-up of 12 months, the 12-mo PFS was 25.2% (95%CI:13.6-38.5%) and median PFS 5.5 months (95%CI:3.7-10.0). The 12-mo overall survival (OS) was 49.4% (95%CI:30.7-65.7%) (fig. 1). Nine patients were alive and in continuous response at time of the data cut-off. 91% of the patients experienced grade > 2 adverse events (AE): neutropenia (58%), infections (28%), gastrointestinal (19%), skin (16%) and thrombocytopenia (13%). SARS-COV-2 infection occurred in 19% with 5 deaths. CMV reactivation occurred in 47%, but without infection. Febrile neutropenia was recorded in 2.8%. AEs led to dose interruptions in 19%.

Since the slow recruitment, the unfavorable safety profile and the emerging of potentially more effective new treatment options in this setting of patient, the study was interrupted prematurely by steering committee decision.

Conclusions: Copa-RB study was conducted in a difficult-to treat R/R DLBCL cohort (elderly, advanced stage) during COVID pandemic that affected its management. Copa-RB induced a good ORR, but it was short lasting with unfavorable safety profile, so the overall activity was modest and did not support further the development of this combination in this setting of patients. A subset of patients had a long-lasting response. A mutational study is ongoing to identify molecular pathways potentially predictive of response to the combination

Disclosures: Tucci: Janssen: Other; Takeda: Other; Gentili: Other; Kiowa Kiryn: Other; Beigene: Other; Sanofi: Other; Eli Lilly: Other. Gini: Takeda: Consultancy; Gentili: Consultancy; Incyte: Consultancy; Roche: Consultancy. Arcari: Janssen, Abbvie, Takeda, Servier: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau. Vitolo: Bayer: Membership on an entity's Board of Directors or advisory committees; Genmab: Membership on an entity's Board of Directors or advisory committees; Gilead: Membership on an entity's Board of Directors or advisory committees; Novartis: Membership on an entity's Board of Directors or advisory committees; AbbVie: Other: Lecture Fees; Incyte: Other: Lecture Fees; Janssen: Other: Lecture Fees; Roche: Other: Lecture Fees; Servier: Other: Lecture Fees.

OffLabel Disclosure: Copanlisib is an OffLabel drug for DLBCL

*signifies non-member of ASH